The ANGPTL3 gene helps control how your body handles fats in the blood, including triglycerides, LDL cholesterol, and HDL cholesterol. If this gene does not work properly, blood fat levels can be much lower than usual, a pattern called familial combined hypolipidemia. Many people with ANGPTL3 variants feel well in daily life, and some studies link reduced ANGPTL3 activity with a lower chance of coronary artery disease.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate activities in the body. Some genes provide the directions for producing proteins, the parts of cells that do the work. Others mainly help determine when certain processes happen, where they happen, and how strongly they are carried out. Together, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medications. To explore this topic in more detail, you can learn more in the LearnHub.
Overview
ANGPTL3Gene function
What if the gene works
The ANGPTL3 gene helps your liver regulate how fats are processed in the blood. It helps control triglyceride, LDL cholesterol, and HDL cholesterol levels.
Risk
What if the gene does not work
Variants in the ANGPTL3 gene can lower cholesterol and triglyceride levels. Milder variants may cause smaller changes, while more severe variants, especially in both copies, cause familial combined hypolipidemia, usually with few or no symptoms.
Treatment
What does that mean for your treatment
No ANGPTL3-specific treatment or drug choice is currently established for people who carry a pathogenic or loss-of-function variant in the ANGPTL3 gene. The ANGPTL3 gene is, however, a well-studied drug target: ANGPTL3-blocking treatment such as evinacumab is used in selected severe cholesterol conditions to lower blood fats, whether or not a person carries an ANGPTL3 variant.
Conditions associated with ANGPTL3
Gene function
What if the gene works
Your body uses the ANGPTL3 gene to help manage fats moving through the bloodstream. Made mainly in the liver, its protein helps set the pace for how quickly certain blood fats are cleared. That steady control supports everyday energy use in muscles, fat tissue, and the liver.
The ANGPTL3 gene helps slow the breakdown of triglycerides, a main form of fat carried in blood. It does this in part by calming lipoprotein lipase (an enzyme that clears triglycerides from blood).
Its protein also regulates endothelial lipase (an enzyme that affects HDL, a blood fat linked with cholesterol transport). This is one way the ANGPTL3 gene helps control blood fats during everyday metabolism.
By setting the pace of fat clearance after meals, this gene helps guide when tissues use fat for fuel or store it. This supports a smooth flow of energy between the liver, muscles, and fat tissue.
What is a variant?
A genetic variant is a minor difference in the DNA sequence of a gene. These differences are common and are part of normal human diversity, including variation in appearance, metabolism, and the way the body responds to environmental influences. Many do not cause any noticeable effect and simply represent natural genetic variation. Sometimes, though, a variant changes how a gene works more significantly and can contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the ANGPTL3 gene can make the ANGPTL3 protein less able to slow the enzymes that clear fats from the blood. Some ANGPTL3 gene variants only partly reduce protein activity, while more severe variants can stop the protein from being made at all or create an unstable protein that is broken down early. This range of effect can influence how strongly blood fat levels fall, and two more disruptive variants often underlie familial combined hypolipidemia.
How variants are linked to conditions
Pathogenic variants in the ANGPTL3 gene cause familial combined hypolipidemia, an inherited condition marked by very low LDL cholesterol, HDL cholesterol, and triglyceride levels. In this setting, ANGPTL3 gene variants linked to familial combined hypolipidemia can confirm the diagnosis. Some other variants in the ANGPTL3 gene are associated with lower risk of coronary artery disease, but these risk patterns do not by themselves diagnose heart disease.
A variant is not necessarily a diagnosis
Variants are a usual feature of human biology and are widely found in the general population. Most do not directly affect health and instead reflect normal human diversity. For many genes, having a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some situations, though, one well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broad, clear evidence on specific factors that change health risk in a predictable way for people with ANGPTL3 changes. In general, overall heart and metabolic health still depends on many other genes, family history, and everyday factors such as smoking, diet, exercise, blood pressure, and diabetes.
Inheritance of ANGPTL3 variants
ANGPTL3-related familial combined hypolipidemia is inherited in an autosomal recessive pattern. This means a person usually develops the condition only if they inherit two disease-causing variants in the ANGPTL3 gene, one from each parent. Parents who each carry one variant are typically called carriers, and with each pregnancy they have a 25% chance of having a child with the condition, a 50% chance of having a child who is a carrier, and a 25% chance of having a child who inherits neither variant.
What does my ANGPTL3 result mean for my family?
For ANGPTL3, the best-established inherited condition is passed down in a recessive way, so close relatives may also carry the gene change even if they feel well. Brothers and sisters could have the same condition or be carriers, and parents are often carriers. For many families, this means relatives may want to learn whether low cholesterol and low triglyceride levels in the family could be linked to the same ANGPTL3 result.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the ANGPTL3 gene, genetic testing for ANGPTL3 variants usually studies DNA from a blood or saliva sample. A lab reads the gene for changes linked with inherited low cholesterol and triglyceride levels, then classifies them as harmful, harmless, or unclear.
When should I consider getting a genetic test?
Genetic testing may be worth discussing if blood tests repeatedly show unusually low cholesterol and triglyceride levels, especially if the same pattern runs in your family. Testing for ANGPTL3 can help explain an inherited low-blood-fat condition and separate it from other causes of very low cholesterol.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how much it explains depends on the condition and the kind of variant involved. Many factors, including lifestyle, environment, age, and medical history, influence how the body functions over time. For some conditions, especially those shaped by many genes, genetic information offers context rather than certainty and is most helpful when considered alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body responds to medicines. Some people break down or move a drug through the body differently, so the same treatment may work better for one person, have less effect in another, or cause more side effects. These differences are common and are one reason medication response can vary from person to person.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in a person’s genes can affect the way they respond to medications. It focuses on gene drug patterns to help explain why the same treatment may work differently in different people. With many medicines, genes can influence both how powerfully a drug works and how the body handles it. This information can support treatment choices that are more informed and more tailored to the individual. More detailed information on this topic is available in the LearnHub.
Drugs influenced by the ANGPTL3 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choices, so questions about medicines or side effects are best discussed with your doctor. ANGPTL3 is being studied mainly as a cholesterol-related treatment target rather than a gene doctors use to predict medication response.
History
ANGPTL3 entered the scientific literature in the late 1990s, during a period when researchers were sorting newly identified genes involved in metabolism. A key turning point came in the 2000s, when rare families with unusually low cholesterol and triglyceride levels were found to carry variants in the ANGPTL3 gene. Initially understood only through visible traits, later recognized as tied to a specific gene, this finding helped connect an inherited pattern with a distinct genetic cause. From these first observations, research expanded steadily. Interest grew further as ANGPTL3 became a target for new cholesterol lowering treatments, especially for people with inherited forms of very high cholesterol. Its history is now closely linked with the move from gene discovery to precision medicine.